This antibody SI-B001 shows an significant step forward in cancer care of relapsed multiple myeloma. This first-in-class antibody specifically interacts with BCMA within myeloma tumors, triggering BCMA-dependent cellular cytotoxicity or enhancing anti-tumor immune reactions. Initial patient resul